Aspira Womens Health (FRA:CUL) Total Liabilities : €7.85 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Aspira Womens Health Total Liabilities?

Aspira Womens Health's Total Liabilities for the quarter that ended in Mar. 2024 was €7.85 Mil.

Aspira Womens Health's quarterly Total Liabilities declined from Sep. 2023 (€8.73 Mil) to Dec. 2023 (€7.91 Mil) and declined from Dec. 2023 (€7.91 Mil) to Mar. 2024 (€7.85 Mil).

Aspira Womens Health's annual Total Liabilities increased from Dec. 2021 (€9.65 Mil) to Dec. 2022 (€9.81 Mil) but then declined from Dec. 2022 (€9.81 Mil) to Dec. 2023 (€7.91 Mil).

Aspira Womens Health Total Liabilities Historical Data

The historical data trend for Aspira Womens Health's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health Total Liabilities Chart

Aspira Womens Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

4.58

8.13

9.65

9.81

7.91

Aspira Womens Health Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															9.97	7.61	8.73	7.91	7.85

Aspira Womens Health Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aspira Womens Health's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.694	+	(1.703	+	1.514
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	7.91

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	5.742	-	-2.169
	=	7.91

Aspira Womens Health's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4.87	+	(1.687	+	1.288
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	7.85

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	6.591	-	-1.254
	=	7.85

Aspira Womens Health Total Liabilities Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aspira Womens Health (FRA:CUL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (FRA:CUL) » Definitions » Total Liabilities

Comparable Companies

DRIO OCX ENZ BIAF PRE TTOO XGN DMTK SLDX MYNZ TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

AWH:USA

Address

12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738

Website

https://www.aspirawh.com

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Aspira Womens Health (FRA:CUL) Headlines

No Headlines